GLP-1/GIPEli Lilly

Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist, making it unique among weight loss medications. It targets two hormones instead of one, potentially offering enhanced effectiveness.

ZepboundMounjaro

Brand-Name Cost

$1,000-1,200/month

Compounded Cost

$199-399/month

Type

GLP-1/GIP Agonist

How Tirzepatide Works

Tirzepatide activates both GIP and GLP-1 receptors, which work together to reduce appetite, slow gastric emptying, and improve insulin sensitivity. The dual mechanism may explain its superior weight loss results in some studies.

Effectiveness

Clinical trials show an average weight loss of 20-22% of body weight over 72 weeks. The SURMOUNT-5 trial showed tirzepatide outperformed semaglutide (20.2% vs 13.7% weight loss).

Dosing

Weekly injection starting at 2.5mg, gradually increasing to maintenance doses of 5mg, 10mg, or 15mg based on response and tolerability.

FDA-Approved Uses

Weight loss (Zepbound)
Type 2 diabetes (Mounjaro)

Common Side Effects

Nausea

Diarrhea

Vomiting

Constipation

Abdominal pain

Decreased appetite

Most side effects are mild and improve over time as your body adjusts to the medication.

Important Warnings

•Not for people with personal/family history of medullary thyroid carcinoma
•Not for people with Multiple Endocrine Neoplasia syndrome type 2
•Use caution with history of pancreatitis

Where to Get Tirzepatide

Hims/Hers

From $199/mo

Henry Meds

From $149/mo

View All Providers

Get GLP-1 Updates

Weekly pricing updates, FDA news, and new provider reviews delivered to your inbox.

We may earn commissions from provider links. This doesn't affect our rankings. Disclosure